- Home
- BG vs MRNA Comparison
BG vs MRNA Comparison
Compare BG & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BG | MRNA |
|---|---|---|
| Founded | 1818 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.5B | 21.6B |
| IPO Year | 2023 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BG | MRNA |
|---|---|---|
| Price | $126.46 | $50.03 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 12 |
| Target Price | ★ $132.29 | $34.27 |
| AVG Volume (30 Days) | 1.5M | ★ 5.0M |
| Earning Date | 04-29-2026 | 05-01-2026 |
| Dividend Yield | ★ 2.28% | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $70,329,000,000.00 | $19,263,000,000.00 |
| Revenue This Year | $36.36 | $9.36 |
| Revenue Next Year | $3.40 | $15.43 |
| P/E Ratio | $358.26 | ★ N/A |
| Revenue Growth | ★ 32.43 | 4.29 |
| 52 Week Low | $71.60 | $22.28 |
| 52 Week High | $134.87 | $59.55 |
Technical Indicators
Market Signals| Indicator | BG | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 51.60 | 54.60 |
| Support Level | $117.57 | $45.09 |
| Resistance Level | $126.62 | $54.50 |
| Average True Range (ATR) | 4.01 | 2.87 |
| MACD | 0.08 | 0.31 |
| Stochastic Oscillator | 48.24 | 80.12 |
Price Performance
Historical ComparisonAbout BG Bunge Limited
Bunge Global SA is an agribusiness solutions company, connecting farmers to consumers and delivering essential food, feed and fuel to the globe. The company segments include Soybean Processing and Refining; Softseed Processing and Refining; Other Oilseeds Processing and Refining; Grain Merchandising and Milling; and Corporate and Other. It generates maximum revenue from the Soybean Processing and Refining segment, which includes integrated business principally involved in the purchase, storage, transportation, processing, distribution, refining, marketing, and sale of soybeans and soybean related products, as well as biodiesel and fertilizer production and distribution. Geographically, the company operates in United States, Switzerland, Netherlands, and Rest of the World.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.